Intravenous (IV) administration of the antiplatelet agent tirofiban for 72 hours was associated with a reduction in early neurologic deterioration compared with oral aspirin therapy in patients with acute ischemic stroke, in the randomized TREND trial. The results were presented at the International Stroke Conference 2024, held on February 7-9 in Phoenix, Arizona. Lead author...